Galectin-10, a potential biomarker of eosinophilic airway inflammation

PLoS ONE

Volumn 7, Issue 8, 2012, Pages

  Chua, Justin C ^a   Douglass, Jo A ^a   Gillman, Andrew ^a   O'Hehir, Robyn E ^a   Meeusen, Els N ^b  

^a ALFRED HOSPITAL   (Australia)

^b MONASH UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; GALECTIN; GALECTIN 10; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; EOSINOPHIL COUNT; EOSINOPHILIA; EOSINOPHILIC AIRWAY INFLAMMATION; FEMALE; HUMAN; HUMAN CELL; MALE; RESPIRATORY TRACT INFLAMMATION; SPUTUM ANALYSIS; SPUTUM LEVEL; WESTERN BLOTTING;

ADULT; BIOLOGICAL MARKERS; BLOTTING, WESTERN; CASE-CONTROL STUDIES; CELL COUNT; EOSINOPHILS; FEMALE; GALECTINS; HUMANS; INFLAMMATION; MALE; MIDDLE AGED; NEUTROPHILS; RESPIRATORY SYSTEM; SPUTUM;

EID: 84864685114     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0042549     Document Type: Article

References (31)

1. Masoli M, Fabian D, Holt S, Beasley R, ((2004)) Global Initiative for Asthma (GINA) Program ((2004)) The global burden of asthma: executive summary of the GINA Dissemination Committee report. Allergy 59:469-478.
2. Chlumsky J, Striz I, Terl M, Vondracek J, ((2006)) Strategy aimed at reduction of sputum eosinophils decreases exacerbation rate in patients with asthma. Journal of International Medical Research 34:129-139.
3. Global Initiative for Asthma ((2009)) Global Strategy for Asthma Management and Prevention.
4. National Heart Lung and Blood Institute ((2007)) Expert Panel Report 3: Guidelines for the Diagnosis and Management of Asthma.
5. Pavord ID, Brightling CE, Woltmann G, Wardlaw AJ, ((1999)) Non-eosinophilic corticosteroid unresponsive asthma. Lancet 353:2213-2214.
6. Simpson JL, Scott R, Boyle MJ, Gibson PG, ((2006)) Inflammatory subtypes in asthma: assessment and identification using induced sputum. Respirology 11:54-61.
7. Berry M, Morgan A, Shaw DE, Parker D, Green R, et al. ((2007)) Pathological features and inhaled corticosteroid response of eosinophilic and non-eosinophilic asthma. Thorax 62:1043-1049.
8. Green RH, Brightling CE, McKenna S, Hargadon B, Parker D, et al. ((2002)) Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial. The Lancet 360:1715-1721.
9. Simpson JL, McElduff P, Gibson PG, ((2010)) Assessment and reproducibility of non-eosinophilic asthma using induced sputum. Respiration 79:147-151.
10. Jayaram L, Pizzichini MM, Cook RJ, Boulet L-P, Lemière C, et al. ((2006)) Determining asthma treatment by monitoring sputum cell counts: effect on exacerbations. European Respiratory Journal 27:483-494.
11. Leuppi JD, Salome CM, Jenkins CR, Koskela H, Brannan JD, et al. ((2001)) Markers of airway inflammation and airway hyperresponsiveness in patients with well-controlled asthma. European Respiratory Journal 18:444-450.
12. Lovett CJ, Whitehead BF, Gibson PG, ((2007)) Eosinophilic airway inflammation and the prognosis of childhood asthma. Clinical and Experimental Allergy 37:1594-1601.
13. Pavord ID, Shaw D, ((2008)) The use of exhaled nitric oxide in the management of asthma. Journal of Asthma 45:523-531.
14. Smith AD, Cowan JO, Brassett KP, Filsell S, McLachlan C, et al. ((2005)) Exhaled nitric oxide: a predictor of steroid response. American Journal of Respiratory and Critical Care Medicine 172:453-459.
15. Patil SU, Long AA, ((2010)) The usefulness of biomarkers of airway inflammation in managing asthma. Allergy and Asthma Proceedings 31:259-268.
16. Taylor DR, ((2011)) Using biomarkers in the assessment of airways disease. J Allergy Clin Immunol 128:927-934 quiz 935-926.
17. Ackerman SJ, Liu L, Kwatia MA, Savage MP, Leonidas DD, et al. ((2002)) Charcot-Leyden crystal protein (galectin-10) is not a dual function galectin with lysophospholipase activity but binds a lysophospholipase inhibitor in a novel structural fashion. J Biol Chem 277:14859-14868.
18. Porsbjerg C, Lund TK, Pedersen L, Backer V, ((2009)) Inflammatory subtypes in asthma are related to airway hyperresponsiveness to mannitol and exhaled NO. Journal of Asthma 46:606-612.
19. Dvorak AM, ((2005)) Immunogold ultrastructural techniques identify subcellular sites of chymase, Charcot-Leyden crystal protein, and histamine in basophils and mast cells. Chemical Immunology & Allergy 85:89-97.
20. Bryborn M, Hallden C, Sall T, Cardell LO, ((2010)) CLC- a novel susceptibility gene for allergic rhinitis? Allergy 65:220-228.
21. De Re V, Simula MP, Cannizzaro R, Pavan A, De Zorzi MA, et al. ((2009)) Galectin-10, eosinophils, and celiac disease. Annals of the New York Academy of Sciences 1173:357-364.
22. Devouassoux G, Pachot A, Laforest L, Diasparra J, Freymond N, et al. ((2008)) Galectin-10 mRNA is overexpressed in peripheral blood of aspirin-induced asthma. Allergy 63:125-131.
23. Dor PJ, Ackerman SJ, Gleich GJ, ((1984)) Charcot-Leyden crystal protein and eosinophil granule major basic protein in sputum of patients with respiratory diseases. American Review of Respiratory Disease 130:1072-1077.
24. Ghafouri B, Irander K, Lindbom J, Tagesson C, Lindahl M, ((2006)) Comparative proteomics of nasal fluid in seasonal allergic rhinitis. Journal of Proteome Research 5:330-338.
25. Dunphy JL, Barcham GJ, Bischof RJ, Young AR, Nash A, et al. ((2002)) Isolation and Characterization of a Novel Eosinophil-specific Galectin Released into the Lungs in Response to Allergen Challenge. The Journal of Biological Chemistry 277:14916-14924.
26. Carlsson MC, Balog CI, Kilsgard O, Hellmark T, Bakoush O, et al. Different fractions of human serum glycoproteins bind galectin-1 or galectin-8, and their ratio may provide a refined biomarker for pathophysiological conditions in cancer and inflammatory disease. Biochim Biophys Acta.
27. Juniper E, O'Byrne P, Guyatt G, Ferrie P, King D, ((1999)) Development and validation of a questionnaire to measure asthma control. European Respiratory Journal 14:902.
28. Miller M, Hankinson J, Brusasco V, Burgos F, Casaburi R, et al. ((2005)) Standardisation of spirometry. European Respiratory Journal 26:319.
29. Pavord ID, Pizzichini MM, Pizzichini E, Hargreave FE, ((1997)) The use of induced sputum to investigate airway inflammation. Thorax 52:498-501.
30. Petsky HL, Kynaston JA, Turner C, Li AM, Cates CJ, et al. ((2007)) Tailored interventions based on sputum eosinophils versus clinical symptoms for asthma in children and adults. Cochrane Database of Systematic Reviews pp. CD005603.
31. Al-Samri M, Benedetti A, Préfontaine D, Olivenstein R, Lemière C, et al. ((2010)) Variability of sputum inflammatory cells in asthmatic patients receiving corticosteroid therapy: A prospective study using multiple samples. Journal of Allergy and Clinical Immunology.